Thus, our study may be the first step toward a specific treatment for FOXP1 syndrome that not only alleviates individual symptoms but also targets two of the overarching causes of the disorder, namely the imbalance between direct and indirect pathway activity due to reduced Pde10a levels and presumed underlying neuroinflammation. Here, PDE10A is linked to Down syndrome.